A new partnership between OneOme and ProZed Pharmacy Solutions brings the power of personalized medicine to Canada. Minnesota-based OneOme will provide its RightMed pharmacogenomics platform exclusively to customers of ProZed Pharmacy Solutions at Northern Shores Pharmacy in North Bay, Ontario as the first step in a nationwide launch. The partnership is the precision medicine company’s first entry into the Canadian retail pharmacy market.
“ProZed Pharmacy Solutions is the first company to offer OneOme’s RightMed PGx test in a retail pharmacy setting in Canada and we are glad to be expanding our efforts to make prescriptions personal,” Paul Owen, CEO of OneOme, said. “Through this partnership, we hope to not only improve health and lower costs, but also to determine how communities globally can best implement pharmacogenomic testing and support.”
Dr. Richard Procunier, co-founder of ProZed Pharmacy Solutions said. “Pharmacists at ProZed are specially trained and well-equipped to help patients customize their medications by using OneOme’s RightMed test and supporting tool, the RightMed Advisor. ProZed’s Personamed medication management service will be using OneOme’s products to provide patients and their physicians with understandable and actionable prescription guidance.” Procunier also is owner of Northern Shores Pharmacy in North Bay.
Pharmacogenomics (PGx) has the potential to reduce adverse drug reactions, lower re-hospitalization rates and improve health outcomes by analyzing how a person’s genes may predict their response to medications, according to OneOme.
As part of this partnership, ProZed Pharmacy Solutions will launch a patient study that focuses on the benefits of implementing pharmacogenomic testing in a community pharmacy setting. The goal of the research study is to measure whether using PGx testing in a community pharmacy setting improves health and economic outcomes.
The findings from the study will complement a recent research paper, which found that providers combining genetic testing and support tools significantly reduced hospitalizations for home health patients using multiple mediations. [Elliot et al., February 2017, as cited in Procunier 2017, J Psychiatry Ment Health]
OneOme’s pharmacogenomic testing and clinical support tools are easy-to-use, intuitive and ready to be integrated into clinical practices. The RightMed pharmacogenomic test covers 22 genes, 340+ medications for more than 20 medical indications and it can be integrated into electronic medical records (EMRs). To date, 160+ hospitals and clinics from fifteen different countries have ordered OneOme’s RightMed test, and OneOme continues to build research and commercial partnerships across the globe.
ProZed offers the Personamed medication therapy management service. By working with pharmacists and pharmacies, the company facilitates PGx testing and consultations between a patient and their physician to provide understandable and actionable prescription guidance.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic.
(Source: PR Newswire)